GeneReach Biotechnology
GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. The company offers various equipment, such as POCKIT Central Nucleic Acid Analyzer, POCKIT Micro Series, taco mini Automatic Nucleic Acid Extraction System, taco Prep Homogenization System, and cubee Mini-Centrifuge; reagents and consumables, including Human IVD Assa… Read more
GeneReach Biotechnology (4171) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.004x
Based on the latest financial reports, GeneReach Biotechnology (4171) has a cash flow conversion efficiency ratio of -0.004x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-2.52 Million) by net assets (NT$591.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
GeneReach Biotechnology - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how GeneReach Biotechnology's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
GeneReach Biotechnology Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GeneReach Biotechnology ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Emperor International Holdings Limited
F:EM3A
|
0.002x |
|
Dolphin Offshore Enterprises (India) Limited
NSE:DOLPHIN
|
N/A |
|
Marvipol S.A.
WAR:MVP
|
-0.061x |
|
SJ Group Co. Ltd
KQ:306040
|
-0.034x |
|
Ozerden Plastik Sanayi
IS:OZRDN
|
0.718x |
|
Palisades Goldcorp Ltd.
PINK:PLGDF
|
-0.009x |
|
Getchell Gold Corp
OTCQB:GGLDF
|
-0.390x |
|
Menon Bearings Limited
NSE:MENONBE
|
0.082x |
Annual Cash Flow Conversion Efficiency for GeneReach Biotechnology (2017–2024)
The table below shows the annual cash flow conversion efficiency of GeneReach Biotechnology from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$725.49 Million | NT$-23.22 Million | -0.032x | +28.61% |
| 2023-12-31 | NT$862.44 Million | NT$-38.67 Million | -0.045x | -113.83% |
| 2022-12-31 | NT$1.10 Billion | NT$357.63 Million | 0.324x | +1.12% |
| 2021-12-31 | NT$1.09 Billion | NT$348.99 Million | 0.321x | +62.01% |
| 2020-12-31 | NT$857.76 Million | NT$169.82 Million | 0.198x | +1148.98% |
| 2019-12-31 | NT$593.05 Million | NT$-11.19 Million | -0.019x | -202.24% |
| 2018-12-31 | NT$311.15 Million | NT$5.74 Million | 0.018x | +167.78% |
| 2017-12-31 | NT$250.63 Million | NT$-6.83 Million | -0.027x | -- |